Summary characteristics by treatment group
| Characteristic . | Thrombolytic regimen . | Standard anticoagulation . | P . |
|---|---|---|---|
| Median age, y (range) | 9 (1-19) | 13 (0.7-17) | .66 |
| Median lag to therapy, d (range) | 7 (1-42) | 6 (1-60) | 1.00 |
| Median venous segments thombosed (range) | 2 (1-5) | 3 (1-4) | .86 |
| PE at diagnosis | 44.4% (4/9) | 7.7% (1/13) | .04 |
| Central venous catheter | 33.3% (3/9) | 23.1% (3/13) | .60 |
| Median FVIII, U/dL (range) | 245 (157-359) | 188 (122-286) | .33 |
| Median D-dimer, ng/mL (range) | 1854 (266-5250) | 1335 (<230-5250) | .97 |
| Genetic thrombophilia | 5.0% (4/8) | 33.3% (4/12) | .46 |
| Lupus anticoagulant | 57.1% (4/7) | 58.3% (7/12) | .96 |
| APA syndrome | 42.9% (3/7) | 27.3% (3/11) | .49 |
| Acquired thrombophilia | 62.5% (5/8) | 66.7% (8/12) | .85 |
| Thrombus resolution | 88.9% (8/9) | 41.7% (5/12) | .03 |
| PTS | 22.2% (2/9) | 76.9% (10/13) | .01 |
| PTS with both physical and functional abnormalities | 11.1% (1/9) | 30.8% (4/13) | .28 |
| Characteristic . | Thrombolytic regimen . | Standard anticoagulation . | P . |
|---|---|---|---|
| Median age, y (range) | 9 (1-19) | 13 (0.7-17) | .66 |
| Median lag to therapy, d (range) | 7 (1-42) | 6 (1-60) | 1.00 |
| Median venous segments thombosed (range) | 2 (1-5) | 3 (1-4) | .86 |
| PE at diagnosis | 44.4% (4/9) | 7.7% (1/13) | .04 |
| Central venous catheter | 33.3% (3/9) | 23.1% (3/13) | .60 |
| Median FVIII, U/dL (range) | 245 (157-359) | 188 (122-286) | .33 |
| Median D-dimer, ng/mL (range) | 1854 (266-5250) | 1335 (<230-5250) | .97 |
| Genetic thrombophilia | 5.0% (4/8) | 33.3% (4/12) | .46 |
| Lupus anticoagulant | 57.1% (4/7) | 58.3% (7/12) | .96 |
| APA syndrome | 42.9% (3/7) | 27.3% (3/11) | .49 |
| Acquired thrombophilia | 62.5% (5/8) | 66.7% (8/12) | .85 |
| Thrombus resolution | 88.9% (8/9) | 41.7% (5/12) | .03 |
| PTS | 22.2% (2/9) | 76.9% (10/13) | .01 |
| PTS with both physical and functional abnormalities | 11.1% (1/9) | 30.8% (4/13) | .28 |
Values in parentheses display frequency counts of # affected per total # assessable, unless otherwise indicated. PTS was uniformly assessed at 18-24 months post-diagnosis of deep venous thrombosis, and consisted of either physical exam abnormalities, functional limitations, or both (ie, PTS score ≥ 1; see “Patients, materials, and methods”), except as otherwise noted. Lag to therapy represents time from symptom onset to institution of antithrombotic therapy. Acquired thrombophilia excludes FVIII activity, D-dimer concentration, and the presence of the lupus anticoagulant, which are given separately. Thrombus resolution indicates ≥ 90% thrombus resolution as documented radiologically at one year after diagnosis of deep venous thrombosis.
PE indicates pulmonary embolism; FVIII, factor VIII activity; APA, antiphospholipid antibody.